New academic journal spotlights potential for rare cannabinoids to treat skin conditions
Less popular cannabinoids such as tetrahydrocannabivarin (THCV) and cannabichromene (CBC) may be used to treat skin conditions, according to a new study promoted by InMed Pharmaceuticals Inc. (Nasdaq: INM).
On Tuesday, the company announced the release of a study published in the International Journal of Molecular Sciences which reviews the potential of THCV, CBC, CBGA and CBG to treat various skin disorders. That scientific analysis also examines how those cannabinoids interact with the endocannabinoid system in skin cells.
Utilizing a broadly acclaimed in vitro model of human keratinocytes, biologists investigated how cannabinoids interacted with an assortment of receptors and endocannabinoid system elements. The findings indicated that each cannabinoid had unique biologic activity by way of the endocannabinoid system.